MX2021015292A - Interacciones terapeuticas de leucometiltioninio. - Google Patents
Interacciones terapeuticas de leucometiltioninio.Info
- Publication number
- MX2021015292A MX2021015292A MX2021015292A MX2021015292A MX2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- homeostatic
- downregulation
- therapeutics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a métodos de tratamiento de la enfermedad de Alzheimer o Deterioro Cognitivo Leve los cuales están adaptados para evitar interacciones negativas entre combinaciones de terapéuticos. En particular, se describen tales métodos de tratamiento en los cuales el orden de los terapéuticos es activamente controlado para mitigar la regulación descendente homeostática previo a la administración de agentes terapéuticos activos, por ejemplo, que modifican la enfermedad. En ciertas modalidades, la terapia con tratamientos sintomáticos (tales como modificadores de la actividad de acetilcolina o neurotransmisores de glutamato) puede ser combinada subsecuentemente con el tratamiento que modifica la enfermedad u otro activo. La invención también aplica los hallazgos con relación con la regulación descendente homeostática a nuevos métodos de diseño de ensayos clínico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909493.7A GB201909493D0 (en) | 2019-07-01 | 2019-07-01 | Therapeutic interactions |
| PCT/EP2020/068422 WO2021001380A1 (en) | 2019-07-01 | 2020-06-30 | Therapeutic interactions of leucomethylthioninium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015292A true MX2021015292A (es) | 2022-01-18 |
Family
ID=67540109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015292A MX2021015292A (es) | 2019-07-01 | 2020-06-30 | Interacciones terapeuticas de leucometiltioninio. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230031369A1 (es) |
| EP (1) | EP3989954A1 (es) |
| JP (1) | JP2022538642A (es) |
| KR (1) | KR20220027203A (es) |
| CN (1) | CN114126622A (es) |
| AU (1) | AU2020298758A1 (es) |
| BR (1) | BR112021025256A2 (es) |
| CA (1) | CA3143790A1 (es) |
| GB (1) | GB201909493D0 (es) |
| IL (1) | IL289338A (es) |
| MX (1) | MX2021015292A (es) |
| WO (1) | WO2021001380A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| EA014552B1 (ru) | 2006-03-29 | 2010-12-30 | Уиста Лэборэтэриз Лтд. | 3,7-диамино-10н-фенотиазиновые соли и их применение |
| CN101820884B (zh) | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| EP2954932B1 (en) | 2007-10-03 | 2018-09-19 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| WO2009060191A2 (en) | 2007-11-05 | 2009-05-14 | Wista Laboratories Ltd. | Systems for clinical trials |
| LT2673266T (lt) | 2011-02-11 | 2016-10-10 | Wista Laboratories Ltd. | Fenotiazino diaminio druskos ir jų panaudojimas |
| CN116531386A (zh) | 2016-07-25 | 2023-08-04 | 维斯塔实验室有限公司 | 二氨基吩噻嗪的给药和剂量 |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| IL280361B1 (en) | 2018-07-26 | 2024-03-01 | Wista Lab Ltd | Optimal dosage of diaminophenothiazines in populations |
-
2019
- 2019-07-01 GB GBGB1909493.7A patent/GB201909493D0/en not_active Ceased
-
2020
- 2020-06-30 AU AU2020298758A patent/AU2020298758A1/en active Pending
- 2020-06-30 US US17/620,949 patent/US20230031369A1/en active Pending
- 2020-06-30 CN CN202080048557.6A patent/CN114126622A/zh active Pending
- 2020-06-30 WO PCT/EP2020/068422 patent/WO2021001380A1/en unknown
- 2020-06-30 EP EP20739286.1A patent/EP3989954A1/en active Pending
- 2020-06-30 KR KR1020227003213A patent/KR20220027203A/ko unknown
- 2020-06-30 BR BR112021025256A patent/BR112021025256A2/pt unknown
- 2020-06-30 MX MX2021015292A patent/MX2021015292A/es unknown
- 2020-06-30 JP JP2021577641A patent/JP2022538642A/ja active Pending
- 2020-06-30 CA CA3143790A patent/CA3143790A1/en active Pending
-
2021
- 2021-12-23 IL IL289338A patent/IL289338A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126622A (zh) | 2022-03-01 |
| EP3989954A1 (en) | 2022-05-04 |
| US20230031369A1 (en) | 2023-02-02 |
| KR20220027203A (ko) | 2022-03-07 |
| WO2021001380A1 (en) | 2021-01-07 |
| JP2022538642A (ja) | 2022-09-05 |
| AU2020298758A1 (en) | 2022-02-24 |
| CA3143790A1 (en) | 2021-01-07 |
| GB201909493D0 (en) | 2019-08-14 |
| BR112021025256A2 (pt) | 2022-01-25 |
| IL289338A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2019012884A (es) | Terapia de combinacion. | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| EA202192928A1 (ru) | Терапевтическое лекарственное средство для лечения дискинезии | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| BRPI0412408A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste | |
| MX2022010945A (es) | Usos terapeuticos de compuestos macrociclicos. | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. |